Back to News
Market Impact: 0.35
Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates
Source: zacks.com
Corporate EarningsHealthcare & BiotechAnalyst Estimates
Alnylam Pharmaceuticals reported quarterly earnings of $16.26 per share, beating the Zacks Consensus Estimate of $2.19 per share. Earnings were $2.90 per share in the year-ago quarter.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
ALNY0.70
More News
- Alphabet Erases $500 Billion as ChatGPT, Google AI Cut into Search
- Norwegian shares surge 13% on earnings beat, guidance raise
- Alphabet’s stock has worst day in over 20 years, dragging the S&P 500 to first loss in four days
- Taiwan Stocks Heads for Correction as Global AI Selloff Deepens
- Asia stocks tumble as AI spending concerns deepen; BOJ holds rates
- PC chip plunge wipes out a quarter of Intel’s value